We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 03, 2021

Neratinib + Capecitabine Sustains HRQoL in Patients With HER2+ MBC

Breast Cancer Research and Treatment


Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Neratinib + Capecitabine Sustains Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer and ≥ 2 Prior HER2-Directed Regimens
Breast Cancer Res Treat 2021 Apr 28;[EPub Ahead of Print], B Moy, M Oliveira, C Saura, W Gradishar, SB Kim, A Brufsky, SA Hurvitz, L Ryvo, D Fagnani, S Kalmadi, P Silverman, S Delaloge, J Alarcon, A Kwong, KS Lee, PCS Ang, SGW Ow, SC Chu, R Bryce, K Keyvanjah, J Bebchuk, B Zhang, N Oestreicher, R Bose, N Chan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading